ArriVent BioPharma, Inc. Common Stock (AVBP) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 6 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for AVBP is $44.00, representing a +59.2% upside from the current price of $27.64. Price targets range from a low of $43.00 to a high of $45.00.
